浮华
发表于 2025-3-21 19:05:28
书目名称Breast Cancer Screening in Europe影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0190573<br><br> <br><br>书目名称Breast Cancer Screening in Europe影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0190573<br><br> <br><br>书目名称Breast Cancer Screening in Europe网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0190573<br><br> <br><br>书目名称Breast Cancer Screening in Europe网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0190573<br><br> <br><br>书目名称Breast Cancer Screening in Europe被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0190573<br><br> <br><br>书目名称Breast Cancer Screening in Europe被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0190573<br><br> <br><br>书目名称Breast Cancer Screening in Europe年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0190573<br><br> <br><br>书目名称Breast Cancer Screening in Europe年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0190573<br><br> <br><br>书目名称Breast Cancer Screening in Europe读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0190573<br><br> <br><br>书目名称Breast Cancer Screening in Europe读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0190573<br><br> <br><br>
Alveoli
发表于 2025-3-21 20:52:10
http://reply.papertrans.cn/20/1906/190573/190573_2.png
Painstaking
发表于 2025-3-22 01:36:37
978-3-642-78156-8Springer-Verlag Berlin Heidelberg 1993
过分
发表于 2025-3-22 04:46:08
Overview of European Screening Programmes, knowledge thus obtained to a wider population and, thereby, produce similar results within the everyday setting to those carried out within a strongly motivated trial scenario? Will it be possible to keep a firm check on quality and costs?
infantile
发表于 2025-3-22 09:27:52
Evidence of the Effectiveness of Breast Cancer Screening, be certain that it is effective in its implicit purpose of saving lives, and that the level of benefit it offers outweighs its costs and disadvantages to the women concerned. A large amount of research has therefore been undertaken to measure the value of screening for breast cancer.
痛苦一生
发表于 2025-3-22 16:18:11
Therapeutic Aspects of Screen-Detected Lesions: The Role of the Surgeon, no single treatment suitable for all primary breast cancers as they present with different characteristics which need different types of management. Criteria may now be set out to guide treatment; some based on good evidence and testing, some on what are at present theoretically derived protocols which are being tested in trials.
genesis
发表于 2025-3-22 18:28:07
D. Fleischmann,A. A. Bankier,F. Lefaza knowledge thus obtained to a wider population and, thereby, produce similar results within the everyday setting to those carried out within a strongly motivated trial scenario? Will it be possible to keep a firm check on quality and costs?
蛰伏
发表于 2025-3-22 22:29:48
http://reply.papertrans.cn/20/1906/190573/190573_8.png
山羊
发表于 2025-3-23 05:28:03
M. Kontrus,M. Wiesmayr,Ch. Heroldiveness analysis (CE-analysis). In this case, one effect measure is chosen, e.g. life-years gained, and the analysis tries to define the costs of screening and its effects. For costs one should ideally think of social costs as “opportunity costs”, i.e., benefits forgone because the resources are not
Indebted
发表于 2025-3-23 09:35:46
http://reply.papertrans.cn/20/1906/190573/190573_10.png